Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 102Carcinoma, Non-Small-Cell Lung 84Glioblastoma 77Brain Neoplasms 75Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 51Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Melanoma 35Ovarian Neoplasms 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

Magnetic Resonance Spectroscopy 5Radiosurgery 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Proton Therapy 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04286386 2026-04-29

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

M.D. Anderson Cancer Center

Active not recruiting
130 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03762759 2024-05-17

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Emory University

Phase 2 Unknown
140 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT02624518 2023-04-10

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Stanford University

Phase 2/3 Completed
122 enrolled 8 charts
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡